CD38-directed Cytolytic Antibody class drugs
3 results
Darzalex (daratumumab)
(Daratumumab)Janssen Biotech, Inc.
Usage: DARZALEX is indicated for treating adult patients with multiple myeloma, including those newly diagnosed or with relapsed/refractory disease. It can be used in combination with various therapies or as monotherapy in patients who have undergone multiple prior treatments.
Darzalex faspro (daratumumab and hyaluronidase-fihj (human recombinant))
(daratumumab and hyaluronidase-fihj (human recombinant))Janssen Biotech, Inc.
Usage: DARZALEX FASPRO is indicated for treating adult patients with multiple myeloma and newly diagnosed light chain (AL) amyloidosis. It may be used in various combinations with other therapies and is not recommended for patients with severe cardiac conditions related to AL amyloidosis.
Sarclisa (isatuximab)
(isatuximab)Sanofi-Aventis U.S. LLC
Usage: SARCLISA is indicated for adults with multiple myeloma in combination with other therapies: with pomalidomide and dexamethasone after at least 2 prior therapies; with carfilzomib and dexamethasone for relapsed/refractory cases after 1-3 therapies; and with bortezomib, lenalidomide, and dexamethasone for newly diagnosed patients not eligible for ASCT.